Title: Drugs Acting on the Respiratory System
1Drugs Acting on the Respiratory System
2Introduction
- The respiratory system is subject to many
disorders that interfere with respiration and
other lung functions, including - Respiratory tract infections
- Allergic disorders
- Inflammatory disorders
- Conditions that obstruct airflow (e.g. asthma and
chronic obstructive pulmonary disease, COPD)
3Introduction (Contd)
- Drugs that act on the respiratory system include
- Bronchodilators
- Corticosteroids
- Cromoglycates
- Leukotriene receptor antagonists
- Antihistamines
- Cough preparations
- Nasal decongestants
4Introduction (Contd)
- Drugs acting on the respiratory system,
especially for asthma, can be administered by
inhalation, the advantages are - Enhance therapeutic effects
- Minimize systemic effects
- Rapid relief of acute attacks
5- Asthma is a chronic inflammatory disorder of the
airways in which many cells and cellular elements
play a role, in particular, mast cells,
eosinophils, T lymphocytes, macrophages,
neutrophils, and epithelial cells. In susceptible
individuals, this inflammation causes recurrent
episodes of wheezing, breathlessness, chest
tightness, and coughing, particularly at night or
in the early morning. These episodes are usually
associated with widespread but variable airflow
obstruction that is often reversible either
spontaneously or with treatment. The inflammation
also causes an associated increase in the
existing bronchial hyperresponsiveness to a
variety of stimuli.
6The condition of a patients asthma may change
depending on the environment, activities, and
other factors. When the patient is well,
monitoring and treatment are still needed to
maintain control.
7Introduction (Contd)
- There are various types of inhalation devices
- Metered-dose inhalers (MDIs)
- Pressurized devices that deliver a measured dose
of drug with each activation - With CFC or non-CFC propellant
- Hand-mouth coordination is required
8Introduction (Contd)
- Spacers
- Use with MDIs
- Increase delivery of drug to the lungs decrease
deposition of drug on the oropharyngeal mucosa - Especially important for inhaled corticosteroids
9Introduction (Contd)
- Dry-powder inhalers (DPIs)
- Include Turbuhalers Accuhalers
- Drugs are in the form of dry, micronized powder
- No propellant is employed
- Breath activated, much easier to use
10Introduction (Contd)
- Nebulizers
- Small machine to convert a drug solution into
mist - Droplets in the mist are much finer than those
produced by inhalers - Through face mask or mouth piece held between the
teeth - Take several minutes to deliver the same amount
of drug contained in 1 puff from an inhaler
11Bronchodilators
- Drugs used to relieve bronchospasms associated
with respiratory disorders - Includes
- Adrenoceptor agonists
- Selective ß2-agonists other adrenoceptor
agonists - Antimuscarinic bronchodilators
- Xanthine derivatives
12Bronchodilators (Contd)
- Adrenoceptor agonists
- (i) Selective beta2 agonists
- Stimulate beta2 receptors in smooth muscle of the
lung, promoting bronchodilation, and thereby
relieving bronchospasms - They are divided into short-acting long acting
types
13Bronchodilators (Contd)
Short-acting ß-2 agonists
Drug Formulation Dosage Dosage
Adult Child
Salbutamol Oral tablet (C.R) 8 mg twice daily 4 mg twice daily
Salbutamol Inhaler (MDI), 100mcg/dose 100-200mcg up to three to four times daily Same as adult
Salbutamol Syrup, 2mg/5ml 4 mg three to four times daily 1-2 mg three to four times daily (2 yr)
Terbutaline Oral tablet (S.R) 5-7.5 mg two times daily -
Terbutaline Inhaler 500mg / dose ( Turbuhaler) 500 mcg up to four times daily -
Terbutaline Inhaler 250mg / dose (MDI) 250-500mcg up to 3-4 times daily Same as adult
14Bronchodilators (Contd)
Long-acting ß-2 agonists
Drug Formulation Dosage Dosage
Adult Child
Formoterol Inhaler 4.5mcg / dose (Turbuhaer) 4.5-9 mcg once or twice daily Same as adult
Formoterol Inhaler 9mcg / dose (Turbuhaer) 4.5-9 mcg once or twice daily Same as adult
Salmeterol Inhaler 25mcg / dose (MDI) 50-100 mcg twice daily Same as adult
Salmeterol 50 mcg / dose (Accuhaler) 50 mcg twice Same as adult
15Bronchodilators (Contd)
- Adverse effects
- Tachycardia and palpitations
- Headache
- Tremor
16Bronchodilators (Contd)
- (ii) Other adrenoceptor agonists
- Less suitable less safe for use as
bronchodilators because they are more likely to
cause arrhythmias other side effects - Ephedrine
- Adults 15-60 mg tid po
- Child 7.5-30 mg tid po
- Adrenaline (epinephrine) injection is used in the
emergency treatment of acute allergic and
anaphylactic reactions
17Bronchodilators (Contd)
- Nursing Alerts
- When 2 or more puffs are needed, inform the
patient that at least 1 minute should be allowed
between puffs - Inform the patient that salmeterol and
formoterol, and oral ß-2 agonists should be taken
on a fixed schedule, not on a prn basis - Instruct the patient to report chest pain and
changes in heart rhythm or rate, because ß-2
agonists can cause cardiac stimulation - Contact physician if symptoms such as
nervousness, insomnia, restlessness and tremor
become severe
18Bronchodilators (Contd)
- Antimuscarinic bronchodilators
- Blocks the action of acetylcholine in bronchial
smooth muscle, this reduces intracellular GMP, a
bronchoconstrictive substance - Used for maintenance therapy of
bronchoconstriction associated with chronic
bronchitis emphysema
19Bronchodilators (Contd)
Drug Formulation Dosage Dosage
Adult Child
Ipratropium Inhaler 20 mcg / dose (MDI) 20-80 mcg three to four times a day 20-40 mcg three to four times a day (6yrs)
Tiotropium Inhaler 18 mcg /dose 18 mcg daily Not recommended in children and adolescents
20Bronchodilators (Contd)
- Adverse effects
- Dry mouth
- Nausea
- Constipation
- Headache
21Bronchodilators (Contd)
- Xanthine Derivatives
- Main xanthine used clinically is theophylline
- Theophylline is a bronchodilator which relaxes
smooth muscle of the bronchi, it is used for
reversible airway obstruction - One proposed mechanism of action is that it acts
by inhibiting phosphodiesterase, thereby
increasing cAMP, leading to bronchodialtion
22Bronchodilators (Contd)
Drug Formulation Dosage
Adult Child
Theophylline Tablet 200 / 300 mg (S.R.) 200 300 mg twice daily 10 mg / kg ((2yrs) twice daily
Capsule 50 / 100 mg (Slow release) 7-12 mg/ kg / day in two divided doses 10-16 mg / kg / day in two divided doses (916yrs) 13-20 mg / kg / day in two divided doses (30 months 8 yrs)
Syrup 80 mg / 15 ml 25 ml q6h 1 ml / kg (Max 25 ml) q6h (2yrs)
Aminophylline Injection 25 mg / ml 10 ml 500 mcg / kg / hr IV infusion, adjust when necessary 1 mg / kg /hr (6 months 9 years) 800 mcg / kg /hr (10 16 yrs) IV infusion, adjust when necessary
23Bronchodilators (Contd)
- Adverse effects
- Toxicity is related to theophyline levels
(usually 5-15 µg/ml) - 20-25 µg/ml Nausea, vomiting, diarrhea,
insomnia, restlessness - gt30 µg/ml Serious adverse effects including
dysrhythmias, convulsions, cardiovascular
collapse which may result in death
24Bronchodilators (Contd)
- Nursing alerts
- Plasma theophylline levels should be monitored to
keep it in the therapeutic range, usually 5-15
µg/ml. Dosage should be adjusted to keep
theophylline levels below 20 µg/ml - If patients miss a dose, the following dose
should not be doubled
25Bronchodilators (Contd)
- Nursing alerts (Contd)
- Instruct the patient that sustained-release
formulations should be swallowed intact - Caution patients in consuming caffeine
containing-beverages and other sources of
caffeine. Caffeine can intensify the adverse
effects and decrease the metabolism of
theophylline
26Corticosteroids
- Used for prophylaxis of chronic asthma
- Suppressing inflammation
- Decrease synthesis release of inflammatory
mediators - Decrease infiltration activity of inflammatory
cells - Decrease edema of the airway mucosa
- Decrease airway mucus production
- Increase the number of bronchial beta2 receptors
their responsiveness to beta2 agonists
27Corticosteroids (Contd)
Drug Formulation Dosage Dosage
Adult Child
Beclomethasone Inhaler 50 mcg / dose (MDI) 200 mcg twice daily / 100mcg three to fours times daily Up to 800 mcg daily 50 100 mcg two to four times daily
Beclomethasone Inhaler 250 mcg / dose (MDI) 500 mcg twice daily / 250 mcg four times daily Not recommended
28Corticosteroids (Contd)
Drug (Contd) Formulation Dosage
Adult Child
Budesonide Inhaler 50 mcg / dose (MDI) 200 mcg twice daily Up to 1.6 mg daily 50 400 mcg twice daily Up to 800 mcg daily
Budesonide Inhaler 200mcg / dose (MDI) 200 mcg twice daily Up to 1.6 mg daily 50 400 mcg twice daily Up to 800 mcg daily
Budesonide Inhaler 100 mcg / dose (Turbuhaler) 200-800 mcg once daily in evening Up to 1.6 mg daily in two divided doses 200-800 mcg daily in two divided doses / 200-400 mcg once daily in evening (lt12 yrs)
Budesonide Inhaler 200 mcg / dose (Turbuhaler) 200-800 mcg once daily in evening Up to 1.6 mg daily in two divided doses 200-800 mcg daily in two divided doses / 200-400 mcg once daily in evening (lt12 yrs)
Budesonide Inhaler 400 mcg / dose (Turbuhaler) 200-800 mcg once daily in evening Up to 1.6 mg daily in two divided doses 200-800 mcg daily in two divided doses / 200-400 mcg once daily in evening (lt12 yrs)
29Corticosteroids (Contd)
Drug (Contd) Formulation Dosage Dosage
Adult Child
Fluticasone Inhaler 25mcg / dose (MDI) 100 1000 mcg twice daily 50-100 mcg twice daily (4-16 yrs)
Fluticasone Inhaler 50 mcg / dose (MDI) 100 1000 mcg twice daily 50-100 mcg twice daily (4-16 yrs)
Fluticasone Inhaler 125 mcg / dose (MDI) 100 1000 mcg twice daily 50-100 mcg twice daily (4-16 yrs)
Fluticasone Inhaler 250 mcg / dose (MDI) 100 1000 mcg twice daily 50-100 mcg twice daily (4-16 yrs)
Fluticasone Inhaler 50 mcg / dose (Accuhaler) 100 1000 mcg twice daily 50-100 mcg twice daily (4-16 yrs)
Fluticasone Inhaler 100 mcg / dose (Accuhaler) 100 1000 mcg twice daily 50-100 mcg twice daily (4-16 yrs)
Fluticasone Inhaler 250 mcg / dose (Accuhaler) 100 1000 mcg twice daily 50-100 mcg twice daily (4-16 yrs)
- Acute attacks of asthma should be treated with
short courses of oral corticosteroids, starting
with a high dose for a few days
30Corticosteroids (Contd)
- Adverse effects
- Inhaled corticosteroids
- Candidiasis of the mouth or throat
- Hoarseness
- Can slow growth in children
- Adrenal suppression may occur in long-term, high
dose therapy - Increases the risk of cataracts
31Corticosteroids (Contd)
- Nursing alerts
- Rinse mouth with water without swallowing after
administration to reduce the risk of candidiasis - If taking bronchodilators by inhalation, use
bronchodilators several minutes before the
corticosteroid to enhance application of the
corticosteroid into the bronchial tract
32Combination Products
- May be appropriate for patients stabilised on
individual components in the same proportion - Muscarinic antagonistß2 agonist
- Combivent (20mcg Ipratropium 100mcg salbutamol
/dose, MDI) - Corticosteroidß2 agonist
- Symbicort (160mcg Budesonide4.5mcg Formoterol /
dose, Turbuhaler) - Seretide (SalmeterolFluticasone MDi in Lite,
Medium, Forte preparation Accuhaler)
33Cromoglycates
- Stabilise mast cells prevent the release of
bronchoconstrictive inflammatory substances
when mast cells are confronted with allergens
other stimuli - Only for prophylaxis of acute asthma attacks
34Cromoglycates (Contd)
Drug Formulation Dosage Dosage
Adult Child
Cromoglycate Na Inhaler (1 mg 5mg/dose) 10 mg four times daily, may be increased to six to eight times daily Same as adult
Cromoglycate Na Nebuliser solution 10 mg / ml 2 ml 20 mg four times daily, may be increased six times daily Same as adult
Nedocromil Sodium Inhaler 2 mg / dose (MDI) 4 mg two to four times daily Sames as adult (gt6 yrs)
35Cromoglycates (Contd)
Adverse effects Nursing Alerts
Transient Bronchospasm A selective ß2 agonist such as salbutamol or terbutaline may be inhaled a few minutes beforehand
Others coughing, throat irritation Others coughing, throat irritation
36Cromoglycates (Contd)
- Nursing Alerts (Contd)
- Cromoglycates are for long-term prophylaxis,
patients should administer on a regular schedule
the full therapeutic effects may take several
weeks to develop - They are contraindicated in patients who are
hypersensitive to the drugs
37Leukotriene receptor antagonists
- Act by suppressing the effects of leukotrienes,
compounds that promote bronchoconstriction as
well as eosinophil infiltration, mucus
productions, airway edema - Help to prevent acute asthma attacks induced by
allergens other stimuli - Indicated for long-term treatment of asthma
38Leukotriene receptor antagonists (Contd)
- Dosage
- Montelukast (5 10 mg tablets)
- Adult 10 mg daily at bedtime
- Child
- (2-5yrs) 4 mg daily at bedtime
- (6-14yrs) 5 mg daily at bedtime
39Leukotriene receptor antagonists (Contd)
- Adverse effects
- GI disturbances
- Hypersensitivity reactions
- Restlessness headache
- Upper respiratory tract infection
- Manufacturer advises to avoid these drugs in
pregnancy breast-feeding unless essential
40Management of Chronic Asthma for adults
schoolchildren above 5yrs
- Step 1 Occasional relief short-acting
- beta2 agonist
- Step 2 Add regular preventer therapy
- Standard-dose inhaled corticosteroid
41Management of Chronic Asthma for adults
schoolchildren above 5yrs (Contd)
- Step 3 Add long-acting inhaled beta2 agonist
- dose of inhaled corticosteroid may also be
increased
- Step 4 Add high dose of inhaled corticosteroids
42Management of Chronic Asthma for adults
schoolchildren above 5yrs (Contd)
- Step 5 Add regular oral corticosteroid
- E.g. prednisolone
43Management of Chronic Asthma for adults
schoolchildren above 5yrs (Contd)
- Stepping down
- Review treatment every 3 months
- If symptoms controlled, may initiate stepwise
reduction - Lowest possible dose oral corticosteroid
- Gradual reduction of dose of inhaled
corticosteroid to the lowest dose which controls
asthma
44 45Antihistamines
- H1 receptor antagonists
- Inhibit smooth muscle constriction in blood
vessels respiratory GI tracts - Decrease capillary permeability
- Decrease salivation tear formation
- Used for variety of allergic disorders to prevent
or reverse target organ inflammation
46Antihistamines (Contd)
- All antihistamines are of potential value in the
treatment of nasal allergies, particularly
seasonal allergic rhinitis (hay fever) - Reduce rhinorrhoea sneezing but are usually
less effective for nasal congestion - Are also used topically in the eye, in the nose,
on the skin
47Antihistamines (Contd)
- First-generation H1 receptor antagonists
- Non-selective/sedating
- Bind to both central peripheral H1 receptors
- Usually cause CNS depression (drowsiness,
sedation) but may cause CNS stimulation (anxiety,
agitation), especially in children - Also have substantial anticholinergic effects
48Antihistamines (Contd)
Drug Dosage
Adult Child
Chorpheniramine (4 mg tablet, 2mg/ml Elixir expectorant) 4 mg q4-6hr, max 24 mg daily 1-2yrs 1 mg twice daily 2-12yrs 1- 2 mg q4-6h, Max12 mg daily
Hydroxyzine (25 mg tablet) 25 mg at night 25mg three to four times daily when necessary 6 months-6yrs 5-15 mg daily 50 mg daily in divided dose if needed gt6yrs 15-25 mg daily 50-100 mg daily in divided dose if needed
Diphendramine (10 mg/5ml Elixir) 25-50 mg q4-6h 6.25-25 mg q4-8 hr ( gt1 yr)
49Antihistamines (Contd)
Drug (Contd) Dosage
Adult Child
Promethazine (10 25 mg tablets, 5mg/5ml Elixir) 25 mg at night 25 mg twice daily if needed 2-10yrs 5-25 mg daily in 1 to 2 divided dose
Azatadine (1 mg tablet) 1 mg twice daily 1-12 yrs 0.25-1 mg twice daily
50Antihistamines (Contd)
- Adverse effects
- Sedation
- Dry mouth
- Blurred vision
- GI disturbances
- Headache
- Urinary retention
- Hydroxyzine is not recommended for pregnancy
breast-feeding
51Antihistamines (Contd)
- Second-generation H1 receptor antagonists
- Selective/non-sedating
- Cause less CNS depression because they are
selective for peripheral H1 receptors do not
cross blood-brain barrier - Longer-acting compared to first-generation
antihistamines
52Antihistamines (Contd)
Drug Dosage
Adult Child
Acrivastine (Semprex) 8 mg three times daily Not recommended
Cetirizine (Zyrtec) 10 mg daily 5 mg daily / 2.5 mg twice daily (2-6 yrs)
Desloratadine (Aerius) 5 mg daily 1.25 mg daily (2-5 yrs) 2.5 mg daily (6-11yrs)
Fexofenadine (Telfast) 120-180 mg daily Not recommended
Loratadine (Clarityne) 10 mg daily 5 mg daily (2-5 yrs)
53Antihistamines (Contd)
- Adverse effects
- May cause slight sedation
- Some antihistamines may interact with antifungal,
e.g. ketoconazole antibiotics, e.g.
erythromycin prokinetic drug-- cisapride or
grapefruit juice, leading to potentially serious
ECG changes e.g. Terfenadine
54Cough preparations
- There are three classes of cough preparations
- Antitussives
- Expectorants
- Mucolytics
55Cough preparations (Contd)
- Antitussives
- Drugs that suppress cough
- Some act within the CNS, some act peripherally
- Indicated in dry, hacking, nonproductive cough
that interfere with rest sleep
56Cough preparations (Contd)
Drug Dosage
Codeine phosphate 25mg/5ml syrup 15-30 mg three to four times daily
Pholcodine 5mg/5ml Elixir 5-10 mg three to four times daily
Dextromethorphan 10mg/5ml in Promethazine Compound Linctus 10-30 mg q4-8h
Diphenhydramine 10 mg/ 5ml 25 mg q4h, Max150 mg daily
57Cough preparations (Contd)
- Adverse effects
- Drowsiness
- Respiratory depression (for opioid antitussives)
- Constipation (for opioid antitussives)
- Preparations containing codeine or similar
analgesics are not generally recommended in
children should be avoided altogether in those
under 1 year of age
58Cough preparations (Contd)
- Nursing Alerts
- Observe for excessive suppression of the cough
reflex (inability to cough effectively when
secretions are present). This is a potentially
serious adverse effect because retained
secretions may lead to lungs collapse, pneumonia,
hypoxia, hypercarbia, and respiratory failure
59Cough preparations (Contd)
- Expectorants
- Render the cough more productive by stimulating
the flow of respiratory tract secretions - Guaifenesin is most commonly used
- Available alone as an ingredient in many
combination cough cold remedies
60Cough preparations (Contd)
- Dosage
- Guaifenesin
- 100-400 mg q4h po
- Ammonia Ipecacuaha Mixture
- 10-20 ml three to four times daily po
61Cough preparations (Contd)
- Mucolytics
- Reacts directly with mucus to make it more
watery. This should help make the cough more
productive
62Cough preparations (Contd)
- Dosage
- Acetylcysteine
- 100 mg two to four times daily
- 200 mg two to three times daily
- 600 mg once daily
- Bromhexine
- 8-16 mg three times daily po
- Carbocisteine
- 750 mg three times daily, then 1.5 g daily in
divided doses
63Nasal Decongestants
- Sympathomimetics are used to reduce nasal
congestion - Stimulate alpha1-adrenergic receptors on nasal
blood vessels, which causes vasoconstriction
hence shrinkage of swollen membranes
64Nasal Decongestants (Contd)
- Topical administration
- Response is rapid intense
- Oral administration
- Response are delayed, moderate prolonged
65Nasal Decongestants (Contd)
Drug Formulation Dosage Dosage
Adult Child
Oxymetazoline Nasal Drops 0.025 20 ml - 2-3 drops q12h (2-5 yrs)
Oxymetazoline Nasal Spray 0.05 15 ml 2-3 sprays q12h Same as adults for children gt6 yrs
Phenylephrine Nasal Drops 0.5 10 ml Several drops q2-4h -
Xylometazoline Nasal Drops 0.05 / 0.1 2-3 drops q8-10h (0.1) 2-3 drops q8-10h (2-12 yrs) (0.05)
66Nasal Decongestants (Contd)
- Adverse effects
- Rebound congestion develops with topical agents
when used for more than a few days - CNS stimulation (such as restlessness,
irritability, anxiety and insomnia) occurs with
oral sympathomimetics
67Nasal Decongestants (Contd)
- Adverse effects (Contd)
- Sympathomimetics can cause vasoconstriction by
stimulating a-1 adrenergic receptors. More common
with oral agents - Sympathomimetics cause CNS stimulation, and can
produce effects similar to amphetamine. Hence,
these drugs are subject to abuse
68Nasal Decongestants (Contd)
- Nursing alerts
- Overuse of topical nasal decongestants can cause
rebound congestion, meaning that the congestion
can be worse with the use of drug. To minimise
this, drug therapy should be discontinued
gradually. - The use of topical agents is limited to no more
than 3 to 5 days
69Nasal Decongestants (Contd)
- Nursing alerts (Contd)
- The patients blood pressure and pulse should be
assessed before a decongestant is administered - Inform the patient that nasal burning and
stinging may occur with topical decongestants
70Intranasal Corticosteroids
- Intranasal Corticosteroids
- Most effective for treatment of seasonal and
perennial rhinitis - Have inflammatory actions and can prevent or
suppress all major symptoms of allergic rhinitis
including congestion, rhinorrhea, sneezing, nasal
itching and erythema
71Intranasal Corticosteroids (Contd)
Drug Formulation Dosage Dosage
Adult Child
Beclomethasone Dipropionate Nasal Spray 50 mcg / dose 1 spray in each nostril four times daily Max. 10 sprays / day 4-6 sprays / day
Beclomethasone Dipropionate Nasal Spray 50 mcg dose (Aqueous) 2 applications into each nostril twice to four times daily Max. 400 mcg daily Same as adult (gt6 yrs) Not recommended in children lt6yrs
72Intranasal Corticosteroids (Contd)
Drug (Contd) Formulation Dosage Dosage
Adult Child
Budesonide Nasal Spray 50 mcg / dose (Aqueous) 1-2 sprays into each nostril twice daily after 2-3days 1 spray into each nostril twice daily Not recommended for age 12 yrs or below
Budesonide Turbuhaler 100mcg / dose 400 mcg in the morning given as 2 applications into each nostril then reduce to the smallest amount necessary -
73Intranasal Corticosteroids (Contd)
Drug (Contd) Formulation Dosage Dosage
Adult Child
Fluticasone Nasal Spray 50 mcg / dose (Aqueous) 2 sprays into each nostril in the morning Max 8 sprays/day 1 spray into each nostril in the morning (4-11yrs) Max 4 sprays/day
Mometasone Nasal Spray 50 mcg / dose 2 sprays in each nostril once daily 1spray in each nostril as maintenance Max 8 sprays/day 1 spray in each nostril once daily (3-11yrs)
74Intranasal Corticosteroids (Contd)
- Adverse effects
- Mild
- Most common effects are drying of nasal mucosa
sensations of burning or itching
75Chronic Obstructive Pulmonary Disease (COPD)
- Umbrella term for various conditions
characterized by limitation of airflow that is
not fully reversible - Chronic airflow limitation caused by a mixture of
small airway disease and parenchymal destruction - Airflow limitation is often progressive
- Associated with an abnormal inflammatory response
of lungs to noxious substances - PREVENTABLE and TREATABLE disease
76Relationship between COPD and emphysema/chronic
bronchitis
- Emphysema
- Destruction of the gas exchanging surfaces of the
lung (alveoli) - Pathological term that describes only one of
several structural abnormalities present in
patients with COPD - Chronic bronchitis
- Presence of cough and sputum production for at
least 3 months in each of two consecutive years - Remains a clinically and epidemiologically useful
term, but does not reflect the major impact of
airflow limitation on morbidity and mortality in
COPD patients - The emphasis on these conditions are not included
in the definition of COPD in current relevant
clinical guidelines
77Mechanisms of COPD
78Risk factors
- Genes
- Exposure to particles
- Tobacco smoke
- Occupational dusts, organic and inorganic
- Indoor air pollution from heating and cooking
with biomass in poorly vented dwellings - Outdoor air pollution
- Lung Growth and Development
- Oxidative stress
- Gender (appears to be related to cigarette use?)
- Respiratory infections
- Socioeconomic status
- Nutrition
- Comorbidities (e.g. asthma)
79GOLD report COPD Staging System
Stage / Severity Postbronchodilator FEV1/ FVC and FEV1 pred. Characteristics
Stage I Mild FEV1/FVC lt 0.70 FEV1 80 predicted chronic cough and sputum production may be present, but not always
Stage II Moderate FEV1/FVC lt 0.70 50 FEV1 lt 80 predicted shortness of breath typically developing on exertion and cough and sputum production sometimes also present
Stage III Severe FEV1/FVC lt 0.70 30 FEV1 lt 50 predicted greater shortness of breath, reduced exercise capacity, fatigue, repeated exacerbations that almost always have an impact on patients quality of life
Stage IV Very severe FEV1/FVC lt 0.70 FEV1 lt 30 predicted or FEV1 lt 50 predicted plus chronic respiratory failure quality of life is very appreciably impaired and exacerbations may be life threatening
FEV1 forced expiratory volume in one second FVC forced vital capacity Respiratory failure arterial partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mm Hg) with or without arterial partial pressure of CO2 (PaCO2) greater than 6.7 kPa (50 mm Hg) while breathing air at sea level FEV1 forced expiratory volume in one second FVC forced vital capacity Respiratory failure arterial partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mm Hg) with or without arterial partial pressure of CO2 (PaCO2) greater than 6.7 kPa (50 mm Hg) while breathing air at sea level FEV1 forced expiratory volume in one second FVC forced vital capacity Respiratory failure arterial partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mm Hg) with or without arterial partial pressure of CO2 (PaCO2) greater than 6.7 kPa (50 mm Hg) while breathing air at sea level
80Asthma and COPD
- Underlying cause is different
- Asthma eosinophilic inflammation
- COPD neutrophilic inflammation
- COPD can coexist with asthma
- While asthma can usually be distinguished from
COPD, in some individuals with chronic
respiratory symptoms and fixed airflow limitation
it remains difficult to differentiate the two
diseases
81Differences in causes of COPD and asthma
82Clinical features in COPD and asthma
83Pharmacotherapy
- None of the current available medications can
alter the natural course of COPD or modify the
rate of decline in lung function - Aims (as per GOLD report)
- Relieve symptoms
- Prevent disease progression
- Improve exercise tolerance
- Improve health status
- Prevent and treat complications
- Prevent and treat exacerbations
- Reduce mortality
84Bronchodilators
- Bronchodilator medications are central to symptom
management in COPD - Inhaled therapy is preferred
- The choice between beta agonist, anticholinergic,
theophylline, or combination therapy depends on
availability and individual response in terms of
symptom relief and side effects
85Bronchodilators (Contd)
- Bronchodilators are prescribed on an as-needed or
on a regular basis to prevent or reduce symptoms - Long-acting inhaled bronchodilators are more
effective and convenient - Combining bronchodilators may improve efficacy
and decrease the risk of side effects compared to
increasing the dose of a single bronchodilator
86Corticosteroids
- Effects of oral and inhaled corticosteroids in
COPD are much less dramatic than in asthma, and
their role in the management of stable COPD is
limited to specific indications
87Oral corticosteroids
- Use of a short course (two weeks) of oral
corticosteroids to identify COPD patients who
might benefit from long-term treatment with oral
or inhaled corticosteroids is recommended - Due to lack of evidence of benefit, and the issue
of side effects, long-term treatment with oral
corticosteroids is not recommended in COPD
88Inhaled corticosteroids
- Regular treatment is appropriate for symptomatic
Stage III and Stage IV CPOD and repeated
exacerbations (for example, 3 in the last 3
years) - Treatment has been shown to reduce the frequency
of exacerbations and thus improve health status - More effective when combined with a long-acting
beta agonist
89(No Transcript)
90